Neoadjuvant Trastuzumab and Pertuzumab for Early HER2-Positive Breast Cancer: A Real World Experience.
Benjamin James HallAjay Ashok BhojwaniHelen WongAndrea LawHelen FlintEliyaz AhmedHelen InnesJoanne CliffZaf MalikJulie Elizabeth O'HaganAllison HallRajaram SripadamShaun TolanZulfiqar AliClare HartDouglas ErringtonFarida AlamRosa GiulianiShaveta MehtaSheena KhanduriNicky ThorpRichard JacksonSilvia CicconiCarlo PalmieriPublished in: The breast journal (2022)
This data confirms the efficacy of neoadjuvant chemotherapy combined with dual HER2 directed therapy. While no cardiac toxicity was observed, diarrhoea occurred frequently. The low pCR rate observed in ER and PgR-positive BCs warrants further investigation and consideration of strategies to increase the pCR rate.
Keyphrases
- neoadjuvant chemotherapy
- locally advanced
- positive breast cancer
- lymph node
- rectal cancer
- epidermal growth factor receptor
- sentinel lymph node
- squamous cell carcinoma
- metastatic breast cancer
- radiation therapy
- oxidative stress
- left ventricular
- electronic health record
- big data
- estrogen receptor
- heart failure
- machine learning
- deep learning
- cell therapy
- smoking cessation